
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1781773/publications.pdf Version: 2024-02-01



DETED COLMAN

#	Article	IF	CITATIONS
1	A Long-Term Evaluation of Facebook for Recruitment and Retention in the ENDIA Type 1 Diabetes Pregnancy-Birth Cohort Study. Journal of Diabetes Science and Technology, 2023, 17, 696-704.	2.2	2
2	Longitudinal audit of assessment and pharmaceutical intervention for cardiovascular risk in the Australasian Diabetes Data Network. Diabetes, Obesity and Metabolism, 2022, 24, 354-361.	4.4	3
3	A Randomized Crossover Trial Comparing Glucose Control During Moderate-Intensity, High-Intensity, and Resistance Exercise With Hybrid Closed-Loop Insulin Delivery While Profiling Potential Additional Signals in Adults With Type 1 Diabetes. Diabetes Care, 2022, 45, 194-203.	8.6	24
4	Closed-Loop Insulin Delivery Versus Sensor-Augmented Pump Therapy in Older Adults With Type 1 Diabetes (ORACL): A Randomized, Crossover Trial. Diabetes Care, 2022, 45, 381-390.	8.6	43
5	Women with type 1 diabetes exhibit a progressive increase in gut Saccharomyces cerevisiae in pregnancy associated with evidence of gut inflammation. Diabetes Research and Clinical Practice, 2022, 184, 109189.	2.8	6
6	Driving with Type 1 Diabetes: Real-World Evidence to Support Starting Glucose Level and Frequency of Monitoring During Journeys. Diabetes Technology and Therapeutics, 2022, 24, 350-356.	4.4	1
7	Exercise habits and glucose management among older adults with type 1 diabetes using insulin pumps. Acta Diabetologica, 2022, , 1.	2.5	0
8	Universal Subsidized Continuous Glucose Monitoring Funding for Young People With Type 1 Diabetes: Uptake and Outcomes Over 2 Years, a Population-Based Study. Diabetes Care, 2022, 45, 391-397.	8.6	34
9	Suboptimal glycemic control in adolescents and young adults with type 1 diabetes from 2011 to 2020 across Australia and New Zealand: Data from the Australasian Diabetes Data Network registry. Pediatric Diabetes, 2022, 23, 736-741.	2.9	9
10	Closed-Loop Insulin Delivery Effects on Glycemia During Sleep and Sleep Quality in Older Adults with Type 1 Diabetes: Results from the ORACL Trial. Diabetes Technology and Therapeutics, 2022, 24, 666-671.	4.4	8
11	High prevalence of idiopathic (islet antibodyâ€negative) type 1 diabetes among Indian children and adolescents. Pediatric Diabetes, 2021, 22, 47-51.	2.9	16
12	Clinical Prediction Tool To Identify Adults With Type 2 Diabetes at Risk for Persistent Adverse Glycemia in Hospital. Canadian Journal of Diabetes, 2021, 45, 114-121.e3.	0.8	9
13	Factors that predict glycaemic response to sodiumâ€glucose linked transporter (SGLT) inhibitors. Internal Medicine Journal, 2021, 51, 515-519.	0.8	1
14	Less Nocturnal Hypoglycemia but Equivalent Time in Range Among Adults with Type 1 Diabetes Using Insulin Pumps Versus Multiple Daily Injections. Diabetes Technology and Therapeutics, 2021, 23, 460-466.	4.4	7
15	Determinants of Cardiovascular Risk in 7000 Youth With Type 1 Diabetes in the Australasian Diabetes Data Network. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 133-142.	3.6	7
16	Associations between diet, the gut microbiome and short chain fatty acids in youth with islet autoimmunity and type 1 diabetes. Pediatric Diabetes, 2021, 22, 425-433.	2.9	5
17	Advances in Type 1 Diabetes Prediction Using Islet Autoantibodies: Beyond a Simple Count. Endocrine Reviews, 2021, 42, 584-604.	20.1	31
18	Longitudinal prevalence of inpatient diabetes mellitus in an Australian hospital across five decades: 1972–2019. Internal Medicine Journal, 2021, 51, 814-815.	0.8	6

#	Article	IF	CITATIONS
19	Clycaemic outcomes in Australasian children and adults with Type 1 Diabetes: failure to meet targets across the age spectrum. Internal Medicine Journal, 2021, , .	0.8	5
20	Metabolic outcomes in patients with diabetes mellitus administered SGLT2 inhibitors immediately before emergency or elective surgery: single centre experience and recommendations. British Journal of Anaesthesia, 2021, 127, e5-e7.	3.4	3
21	Evaluation of protocol amendments to the Environmental Determinants of Islet Autoimmunity (ENDIA) study during the COVIDâ€19 pandemic. Diabetic Medicine, 2021, 38, e14638.	2.3	2
22	First Randomized Controlled Trial of Hybrid Closed Loop Versus Multiple Daily Injections or Insulin Pump Using Self-Monitoring of Blood Glucose in Free-Living Adults with Type 1 Diabetes Undertaking Exercise. Journal of Diabetes Science and Technology, 2021, 15, 1399-1401.	2.2	9
23	Type 1 diabetes in pregnancy is associated with distinct changes in the composition and function of the gut microbiome. Microbiome, 2021, 9, 167.	11.1	23
24	Simplifying prediction of disease progression in pre-symptomatic type 1 diabetes using a single blood sample. Diabetologia, 2021, 64, 2432-2444.	6.3	8
25	Benchmarking care outcomes for young adults with type 1 diabetes in Australia after transition to adult care. Endocrinology, Diabetes and Metabolism, 2021, 4, e00295.	2.4	2
26	Meal-time glycaemia in adults with type 1 diabetes using multiple daily injections vs insulin pump therapy following carbohydrate-counting education and bolus calculator provision. Diabetes Research and Clinical Practice, 2021, 179, 109000.	2.8	3
27	Effect of a Hybrid Closed-Loop System on Glycemic and Psychosocial Outcomes in Children and Adolescents With Type 1 Diabetes. JAMA Pediatrics, 2021, 175, 1227.	6.2	54
28	Pancreas size and exocrine function is decreased in young children with recentâ€onset Type 1 diabetes. Diabetic Medicine, 2020, 37, 1340-1343.	2.3	18
29	A physician-initiated double-blind, randomised, placebo-controlled, phase 2 study evaluating the efficacy and safety of inhibition of NADPH oxidase with the first-in-class Nox-1/4 inhibitor, GKT137831, in adults with type 1 diabetes and persistently elevated urinary albumin excretion: Protocol and statistical considerations. Contemporary Clinical Trials, 2020, 90, 105892.	1.8	29
30	Higher frequency of vertebrateâ€infecting viruses in the gut of infants born to mothers with type 1 diabetes. Pediatric Diabetes, 2020, 21, 271-279.	2.9	10
31	Six Months of Hybrid Closed-Loop Versus Manual Insulin Delivery With Fingerprick Blood Glucose Monitoring in Adults With Type 1 Diabetes: A Randomized, Controlled Trial. Diabetes Care, 2020, 43, 3024-3033.	8.6	85
32	Glycaemic trajectory and predictors of suboptimal glycaemic control in people with type 2 diabetes. Internal Medicine Journal, 2020, 50, 1415-1418.	0.8	1
33	Adults With Diabetes Distress Often Want to Talk With Their Health Professionals About It: Findings From an Audit of 4 Australian Specialist Diabetes Clinics. Canadian Journal of Diabetes, 2020, 44, 473-480.	0.8	26
34	A pilot study of the feasibility of empagliflozin in recent-onset type 1 diabetes. Metabolism Open, 2020, 5, 100021.	2.9	1
35	The methionine aminopeptidase 2 inhibitor ZGNâ€1061 improves glucose control and weight in overweight and obese individuals with type 2 diabetes: A randomized, placeboâ€controlled trial. Diabetes, Obesity and Metabolism, 2020, 22, 1215-1219.	4.4	8
36	Clinical trial data validate the C-peptide estimate model in type 1 diabetes. Diabetologia, 2020, 63, 885-886.	6.3	3

#	Article	IF	CITATIONS
37	Successful post-transition engagement can be predicted at the time of transition in type 1 diabetes. Diabetes Research and Clinical Practice, 2020, 163, 108023.	2.8	0
38	Changes in pancreatic exocrine function in young atâ€risk children followed to islet autoimmunity and type 1 diabetes in the <scp>ENDIA</scp> study. Pediatric Diabetes, 2020, 21, 945-949.	2.9	9
39	Glucometric benchmarking in an Australian hospital enabled by networked glucose meter technology. Medical Journal of Australia, 2019, 211, 175-180.	1.7	16
40	Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet, The, 2019, 394, 121-130.	13.7	1,625
41	Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. Lancet, The, 2019, 394, 131-138.	13.7	394
42	Gut microbiome dysbiosis and increased intestinal permeability in children with islet autoimmunity and type 1 diabetes: A prospective cohort study. Pediatric Diabetes, 2019, 20, 574-583.	2.9	86
43	Early Intervention for Diabetes in Medical and Surgical Inpatients Decreases Hyperglycemia and Hospital-Acquired Infections: A Cluster Randomized Trial. Diabetes Care, 2019, 42, 832-840.	8.6	40
44	Distinct Gut Virome Profile of Pregnant Women With Type 1 Diabetes in the ENDIA Study. Open Forum Infectious Diseases, 2019, 6, ofz025.	0.9	32
45	Insights into pituitary tumorigenesis: from Sanger sequencing to next-generation sequencing and beyond. Expert Review of Endocrinology and Metabolism, 2019, 14, 399-418.	2.4	8
46	Hypothyroidism associated with therapy for multiâ€drugâ€resistant tuberculosis in Australia. Internal Medicine Journal, 2019, 49, 364-372.	0.8	6
47	Glucose Control Using a Standard Versus an Enhanced Hybrid Closed Loop System: A Randomized Crossover Study. Diabetes Technology and Therapeutics, 2019, 21, 56-58.	4.4	22
48	MON-457 One in Five Patients Develop Multiple Hormone Deficiencies Following Radiotherapy for Acromegaly or Cushing's Disease. Journal of the Endocrine Society, 2019, 3, .	0.2	0
49	Glucose alert system improves health professional responses to adverse glycaemia and reduces the number of hyperglycaemic episodes in nonâ€critical care inpatients. Diabetic Medicine, 2018, 35, 816-823.	2.3	8
50	Diabetes associated with immune checkpoint inhibition: presentation and management challenges. Diabetic Medicine, 2018, 35, 1283-1290.	2.3	25
51	Effect of 6 months of hybrid closed-loop insulin delivery in adults with type 1 diabetes: a randomised controlled trial protocol. BMJ Open, 2018, 8, e020274.	1.9	7
52	Overnight Counter-Regulatory Hormone Levels and Next Day Glycemia in Adults with Type 1 Diabetes During Closed-Loop Insulin Delivery Versus Sensor-Augmented Pump with Low-Glucose Suspend. Diabetes Technology and Therapeutics, 2017, 19, 438-439.	4.4	0
53	"lt Is Definitely a Game Changer― A Qualitative Study of Experiences with In-home Overnight Closed-Loop Technology Among Adults with Type 1 Diabetes. Diabetes Technology and Therapeutics, 2017, 19, 410-416.	4.4	28
54	Baseline Circulating FGF21 Concentrations and Increase after Fenofibrate Treatment Predict More Rapid Glycemic Progression in Type 2 Diabetes: Results from the FIELD Study. Clinical Chemistry, 2017, 63, 1261-1270.	3.2	11

#	Article	IF	CITATIONS
55	Fournier's gangrene in a man on empagliflozin for treatment of TypeÂ2 diabetes. Diabetic Medicine, 2017, 34, 1646-1648.	2.3	42
56	Dysglycemia and Index60 as Prediagnostic End Points for Type 1 Diabetes Prevention Trials. Diabetes Care, 2017, 40, 1494-1499.	8.6	28
57	Managing hyponatraemia secondary to primary polydipsia: beware too rapid correction of hyponatraemia. Internal Medicine Journal, 2017, 47, 956-959.	0.8	2
58	Type 1 diabetes: a disease of developmental origins. Pediatric Diabetes, 2017, 18, 417-421.	2.9	12
59	Long term risk of severe retinopathy in childhoodâ€onset type 1 diabetes: a data linkage study. Medical Journal of Australia, 2017, 206, 398-401.	1.7	11
60	Factors associated with insulinâ€induced weight gain in an Australian type 2 diabetes outpatient clinic. Internal Medicine Journal, 2016, 46, 834-839.	0.8	8
61	Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-To-Target Randomized Trial. Diabetes Care, 2016, 39, 1702-1710.	8.6	200
62	Australasian Diabetes Data Network. Journal of Diabetes Science and Technology, 2016, 10, 1015-1026.	2.2	28
63	Intense focal pituitary FDG uptake due to intravascular large Bâ€cell lymphoma in pyrexia of unknown origin. American Journal of Hematology, 2016, 91, 1167-1168.	4.1	2
64	Glycemia, Treatment Satisfaction, Cognition, and Sleep Quality in Adults and Adolescents with Type 1 Diabetes When Using a Closed-Loop System Overnight Versus Sensor-Augmented Pump with Low-Glucose Suspend Function: A Randomized Crossover Study. Diabetes Technology and Therapeutics, 2016, 18, 772-783.	4.4	77
65	Redundancy in Glucose Sensing. Journal of Diabetes Science and Technology, 2016, 10, 669-678.	2.2	14
66	Low prevalence of latent autoimmune diabetes in adults in northern India. Diabetic Medicine, 2015, 32, 810-813.	2.3	17
67	Recent advances in type 1 diabetes. Medical Journal of Australia, 2015, 203, 290-293.	1.7	3
68	Divided dosing reduces prednisolone-induced hyperglycaemia and glycaemic variability: a randomized trial after kidney transplantation. Nephrology Dialysis Transplantation, 2014, 29, 698-705.	0.7	37
69	A Practical Limited Sampling Strategy to Predict Free Prednisolone Exposure and Glycemia in Kidney Transplant Recipients. Therapeutic Drug Monitoring, 2014, 36, 18-23.	2.0	3
70	Severe hypoglycaemia and its association with psychological well-being in Australian adults with type 1 diabetes attending specialist tertiary clinics. Diabetes Research and Clinical Practice, 2014, 103, 430-436.	2.8	74
71	A randomised controlled trial of high dose vitamin D in recent-onset type 2 diabetes. Diabetes Research and Clinical Practice, 2014, 106, 576-582.	2.8	32
72	Obesity is associated with retinopathy and macrovascular disease in type 1 diabetes. Obesity Research and Clinical Practice, 2014, 8, e178-e182.	1.8	52

#	Article	IF	CITATIONS
73	Higher body mass index in adults at diagnosis of the slowly progressive form of type 1 diabetes mellitus is associated with lower risk HLA genes. Diabetes Research and Clinical Practice, 2014, 104, e69-e71.	2.8	17
74	Environmental determinants of islet autoimmunity (ENDIA): a pregnancy to early life cohort study in children at-risk of type 1 diabetes. BMC Pediatrics, 2013, 13, 124.	1.7	59
75	Screening for New-Onset Diabetes After Kidney Transplantation. Transplantation, 2013, 96, 726-731.	1.0	48
76	Fulminant type 1 diabetes in Australia in the absence of humoral and cellular immune responses to pancreatic islet autoantigens. Diabetes Research and Clinical Practice, 2012, 95, e4-e6.	2.8	4
77	Body mass index correlates with ischemic heart disease and albuminuria in long-standing type 2 diabetes. Diabetes Research and Clinical Practice, 2012, 97, 57-62.	2.8	11
78	The role of HbA1c in the diagnosis of diabetes mellitus in Australia. Medical Journal of Australia, 2012, 197, 220-221.	1.7	65
79	New-Onset Diabetes After Kidney Transplantation—Changes and Challenges. American Journal of Transplantation, 2012, 12, 820-828.	4.7	119
80	Associations between the use of metformin, sulphonylureas, or diet alone and cardiovascular outcomes in 6005 people with type 2 diabetes in the FIELD study. Diabetes Research and Clinical Practice, 2011, 94, 284-290.	2.8	16
81	Impact of metabolic syndrome and its components on cardiovascular disease event rates in 4900 patients with type 2 diabetes assigned to placebo in the field randomised trial. Cardiovascular Diabetology, 2011, 10, 102.	6.8	42
82	The impact of socioâ€economic disadvantage on rates of hospital separations for diabetesâ€related foot disease in Victoria, Australia. Journal of Foot and Ankle Research, 2011, 4, 17.	1.9	32
83	Evidence That Nasal Insulin Induces Immune Tolerance to Insulin in Adults With Autoimmune Diabetes. Diabetes, 2011, 60, 1237-1245.	0.6	106
84	An Algorithm Guiding Patient Responses to Real-Time-Continuous Glucose Monitoring Improves Quality of Life. Diabetes Technology and Therapeutics, 2011, 13, 105-109.	4.4	21
85	Natural History of Type 1 Diabetes. , 2011, , 279-292.		0
86	A simplified method to assess affinity of insulin autoantibodies. Clinical Immunology, 2010, 137, 415-421.	3.2	10
87	Evaluation of an Algorithm to Guide Patients With Type 1 Diabetes Treated With Continuous Subcutaneous Insulin Infusion on How to Respond to Real-Time Continuous Glucose Levels: A randomized controlled trial. Diabetes Care, 2010, 33, 1242-1248.	8.6	25
88	Measurement of islet cell antibodies in the Type 1 Diabetes Genetics Consortium: efforts to harmonize procedures among the laboratories. Clinical Trials, 2010, 7, S56-S64.	1.6	24
89	Glycaemic impact of patient-led use of sensor-guided pump therapy in type 1 diabetes: a randomised controlled trial. Diabetologia, 2009, 52, 1250-1257.	6.3	194
90	Weight Gain in Early Life Predicts Risk of Islet Autoimmunity in Children With a First-Degree Relative With Type 1 Diabetes. Diabetes Care, 2009, 32, 94-99.	8.6	88

#	Article	IF	CITATIONS
91	A questionnaire for determining prevalence of diabetes related foot disease (Qâ€DFD): construction and validation. Journal of Foot and Ankle Research, 2009, 2, 34.	1.9	14
92	Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. Lancet, The, 2009, 373, 1780-1788.	13.7	270
93	An evaluation of community-based resources for management of diabetes-related foot disorders in an Australian population. Australian Health Review, 2009, 33, 671.	1.1	10
94	Prospective evaluation of a protocol for reduced glucocorticoid replacement in transsphenoidal pituitary adenomectomy: prophylactic glucocorticoid replacement is seldom necessary. Clinical Endocrinology, 2008, 68, 29-35.	2.4	33
95	Type 1 diabetes: Lessons for other autoimmune diseases?. Journal of Autoimmunity, 2008, 31, 306-310.	6.5	55
96	Autoimmunity to Both Proinsulin and IGRP Is Required for Diabetes in Nonobese Diabetic 8.3 TCR Transgenic Mice. Journal of Immunology, 2008, 180, 4458-4464.	0.8	51
97	The Rising Incidence of Type 1 Diabetes Is Accounted for by Cases With Lower-Risk Human Leukocyte Antigen Genotypes. Diabetes Care, 2008, 31, 1546-1549.	8.6	191
98	The accelerator hypothesis and increasing incidence of type 1 diabetes. Current Opinion in Endocrinology, Diabetes and Obesity, 2008, 15, 321-325.	2.3	65
99	Desirable performance standards for HbA1c analysis a€ [∞] precision, accuracy and standardisation Consensus statement of the Australasian Association of Clinical Biochemists (AACB), the Australian Diabetes Society (ADS), the Royal College of Pathologists of Australasia (RCPA), Endocrine Society of Australia (ESA), and the Australian Diabetes Educators Association (ADEA). Clinical Chemistry and	2.3	55
100	Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet, The, 2007, 370, 1687-1697.	13.7	918
101	New haemoglobin A1c: the way it is reported is about to change?. Internal Medicine Journal, 2007, 37, 213-215.	0.8	8
102	Deficiencies in nutritional intake in patients admitted with diabetesâ€related foot complications. Nutrition and Dietetics, 2007, 64, 186-191.	1.8	4
103	Retrospective data for diabetic foot complications: only the tip of the iceberg?. Internal Medicine Journal, 2006, 36, 197-199.	0.8	13
104	Frequency and Temporal Profile of Poststroke Hyperglycemia Using Continuous Glucose Monitoring. Diabetes Care, 2006, 29, 1839-1844.	8.6	107
105	Responses against islet antigens in NOD mice are prevented by tolerance to proinsulin but not IGRP. Journal of Clinical Investigation, 2006, 116, 3258-3265.	8.2	197
106	Creation of a multidisciplinary, evidence based, clinical guideline for the assessment, investigation and management of acute diabetes related foot complications. Diabetic Medicine, 2005, 22, 127-136.	2.3	56
107	Cyclical Cushing's disease causing recurrent oedema and knee effusions. Internal Medicine Journal, 2005, 35, 201-202.	0.8	1
108	Substance abuse in young patients with type 1 diabetes: easily neglected in complex medical management. Internal Medicine Journal, 2005, 35, 359-361.	0.8	15

#	Article	IF	CITATIONS
109	Latent autoimmune diabetes in adults (LADA) should be less latent. Diabetologia, 2005, 48, 2206-2212.	6.3	294
110	Effectiveness and side effects of thiazolidinediones for type 2Âdiabetes: realâ€life experience from a tertiary hospital. Medical Journal of Australia, 2004, 181, 536-539.	1.7	77
111	Pancreatic Â-Cell Function and Immune Responses to Insulin After Administration of Intranasal Insulin to Humans At Risk for Type 1 Diabetes. Diabetes Care, 2004, 27, 2348-2355.	8.6	178
112	Assessment and management of inpatients with acute diabetes-related foot complications: room for improvement. Internal Medicine Journal, 2004, 34, 229-233.	0.8	27
113	Insulin resistance is a risk factor for progression to Type 1 diabetes. Diabetologia, 2004, 47, 1661-1667.	6.3	203
114	Acute complications of dopamine agonist treatment for macroprolactinoma – how uncommon?. Journal of Clinical Neuroscience, 2004, 11, 825-828.	1.5	8
115	Diabetes Ward Management-Room for Improvement. Journal of Pharmacy Practice and Research, 2004, 34, 95-99.	0.8	2
116	Insular Cortical Ischemia Is Independently Associated With Acute Stress Hyperglycemia. Stroke, 2004, 35, 1886-1891.	2.0	114
117	Late-Onset Autoimmune Diabetes in Relatives of People with Type 1 Diabetes. Annals of the New York Academy of Sciences, 2003, 1005, 370-373.	3.8	7
118	HLA genes associated with autoimmunity and progression to disease in type 1 diabetes. Tissue Antigens, 2003, 61, 146-153.	1.0	61
119	The transition from knowing to doing: teaching junior doctors how to use insulin in the management of diabetes mellitus. Medical Education, 2003, 37, 689-694.	2.1	10
120	Thyrotoxic, hypokalaemic periodic paralysis in Australasian men. Internal Medicine Journal, 2003, 33, 91-94.	0.8	22
121	High Frequency of Type 1B (Idiopathic) Diabetes in North Indian Children With Recent-Onset Diabetes. Diabetes Care, 2003, 26, 2697-2697.	8.6	40
122	Persistent Poststroke Hyperglycemia Is Independently Associated With Infarct Expansion and Worse Clinical Outcome. Stroke, 2003, 34, 2208-2214.	2.0	562
123	The influence of diabetes mellitus and hyperglycaemia on stroke incidence and outcome. Journal of Clinical Neuroscience, 2002, 9, 618-626.	1.5	139
124	Development of autoantibodies to islet antigens during childhood: implications for preclinical type 1 diabetes screening. Pediatric Diabetes, 2002, 3, 144-148.	2.9	12
125	The prevalence of lipodystrophy in an ambulant HIV-infected population: it all depends on the definition. HIV Medicine, 2001, 2, 174-180.	2.2	79
126	Linkage disequilibrium of a type 1 diabetes susceptibility locus with a regulatory IL12B allele. Nature Genetics, 2001, 27, 218-221.	21.4	289

#	Article	IF	CITATIONS
127	Association between rotavirus infection and pancreatic islet autoimmunity in children at risk of developing type 1 diabetes. Diabetes, 2000, 49, 1319-1324.	0.6	330
128	Role of islet autoimmunity in the aetiology of different clinical subtypes of diabetes mellitus in young north Indians. Diabetic Medicine, 2000, 17, 275-280.	2.3	27
129	Clinical features and pathogenesis of thyrotoxicosis in adult Melanesians in Papua New Guinea. Clinical Endocrinology, 2000, 52, 261-266.	2.4	6
130	Cerebrospinal fluid (CSF) rhinorrhoea occurring six days after commencement of bromocriptine for invasive macroprolactinoma. Australian and New Zealand Journal of Medicine, 2000, 30, 399-400.	0.5	10
131	Islet autoimmunity in infants with a Type I diabetic relative is common but is frequently restricted to one autoantibody. Diabetologia, 2000, 43, 203-209.	6.3	82
132	Lowerâ€ i imb amputation and diabetes: the key is prevention. Medical Journal of Australia, 2000, 173, 341-342.	1.7	7
133	Screening for preclinical type 1 diabetes in a discrete population with an apparent increased disease incidence. Pediatric Diabetes, 2000, 1, 193-198.	2.9	3
134	Screening for preclinical type 1 diabetes in a discrete population with an apparent increased disease incidence. Pediatric Diabetes, 2000, 1, 193-198.	2.9	0
135	New classification and criteria for diagnosis of diabetes mellitus. Medical Journal of Australia, 1999, 170, 375-378.	1.7	68
136	Problems with new criteria for diagnosis of diabetes mellitus. Medical Journal of Australia, 1999, 171, 108-109.	1.7	1
137	Lack of association between duration of breast-feeding or introduction of cow's milk and development of islet autoimmunity. Diabetes, 1999, 48, 2145-2149.	0.6	132
138	Aspirin usage in a large teaching hospital diabetes clinic setting. Diabetic Medicine, 1999, 16, 605-608.	2.3	10
139	New classification and criteria for diagnosis of diabetes mellitus. Position Statement from the Australian Diabetes Society, New Zealand Society for the Study of Diabetes, Royal College of Pathologists of Australasia and Australasian Association of Clinical Biochemists. Medical Journal of Australia, 1999, 170, 375-8.	1.7	7
140	New classification and criteria for diagnosis of diabetes mellitus. The Australasian Working Party on Diagnostic Criteria for Diabetes Mellitus. New Zealand Medical Journal, 1999, 112, 139-41.	0.5	16
141	IgG subclass antibodies to glutamic acid decarboxylase and risk for progression to clinical insulin-dependent diabetes. Human Immunology, 1998, 59, 493-499.	2.4	33
142	Antibodies to the Protein Tyrosine Phosphatases IAR and IA-2 are Associated with Progression to Insulin-Dependent Diabetes (IDDM) in First-Degree Relatives At-Risk for IDDM. Autoimmunity, 1998, 28, 15-23.	2.6	17
143	The Prognostic Value of Thyrotropin Receptor Antibody Measurement in the Early Stages of Treatment of Graves' Disease with Antithyroid Drugs. Thyroid, 1998, 8, 119-124.	4.5	83
144	The Melbourne Preâ€Diabetes Study: prediction of type 1 diabetes mellitus using antibody and metabolic testing. Medical Journal of Australia, 1998, 169, 81-84.	1.7	45

#	Article	lF	CITATIONS
145	Evaluation of a New, Rapid and Automated Immunochemiluminometric Assay for the Measurement of Serum Intact Parathyroid Hormone. Annals of Clinical Biochemistry, 1997, 34, 97-103.	1.6	32
146	Glycohaemoglobin: a crucial measurement in modem diabetes management. Medical Journal of Australia, 1997, 167, 96-98.	1.7	27
147	New pieces in the puzzle of diabetes. Lancet, The, 1996, 348, S4.	13.7	5
148	Islet-cell antibodies in malnutrition-related diabetes mellitus from North India. Diabetes Research and Clinical Practice, 1996, 34, 73-78.	2.8	14
149	Markers on Distal Chromosome 2q Linked to Insulin-Dependent Diabetes Mellitus. Science, 1996, 272, 1811-1813.	12.6	109
150	Nephrogenic diabetes insipidus associated with foscarnet—a case report. Journal of Antimicrobial Chemotherapy, 1996, 37, 1179-1181.	3.0	11
151	Clinical and Magnetic Resonance Imaging Correlates of Hypothalamic–Pituitary–Adrenal Axis Function in Depression and Alzheimer's Disease. British Journal of Psychiatry, 1996, 168, 679-687.	2.8	139
152	Measurement of TSH receptor blocking immunoglobulins using3H-adenine incorporation into FRTL-5 and JPO9 cells: use in a child with neonatal hypothyroidism. Clinical Endocrinology, 1995, 42, 39-44.	2.4	11
153	Analysis of Families at Risk for Insulin-Dependent Diabetes Mellitus Reveals that HLA Antigens Influence Progression to Clinical Disease. Molecular Medicine, 1995, 1, 576-582.	4.4	69
154	Similar Peptides from Two β Cell Autoantigens, Proinsulin and Glutamic Acid Decarboxylase, Stimulate T Cells of Individuals at Risk for Insulin-Dependent Diabetes. Molecular Medicine, 1995, 1, 625-633.	4.4	96
155	Disease Sensitivity and Specificity of 52 Assays for Glutamic Acid Decarboxylase Antibodies: The Second International GADAB Workshop. Diabetes, 1995, 44, 636-640.	0.6	139
156	Specific Effects of Radioiodine Treatment on TSAb and TBAb Levels in Patients with Graves' Disease. Thyroid, 1995, 5, 171-176.	4.5	29
157	Reproducibility of the First-Phase Insulin Response to Intravenous Glucose Is Not Improved by Retrograde Cannulation and Arterialization or the Use of a Lower Glucose Dose. Diabetes Care, 1995, 18, 1168-1173.	8.6	16
158	Similar peptides from two beta cell autoantigens, proinsulin and glutamic acid decarboxylase, stimulate T cells of individuals at risk for insulin-dependent diabetes. Molecular Medicine, 1995, 1, 625-33.	4.4	34
159	Hyperinsulinemia Is Not a Cause of Cortisol-Induced Hypertension. American Journal of Hypertension, 1994, 7, 562-565.	2.0	13
160	High Level of Concordance Between Assays for Glutamic Acid Decarboxylase Antibodies: The First International Glutamic Acid Decarboxylase Antibody Workshop. Diabetes, 1994, 43, 1005-1009.	0.6	90
161	The Function of the Hypothalamic–Pituitary–Adrenal Axis in Alzheimer's Disease. British Journal of Psychiatry, 1994, 165, 650-657.	2.8	18
162	Measurement of thyroid stimulating immunoglobulins in a new cell line transfected with a functional human TSH receptor (JPO9 cells), compared with an assay using FRTL-5 cells. Clinical Endocrinology, 1994, 40, 645-652.	2.4	41

#	Article	lF	CITATIONS
163	Antibodies to Glutamic Acid Decarboxylase in At-risk and Clinical Insulin-dependent Diabetic Subjects: Relationship to Age, Sex and Islet Cell Antibody Status, and Temporal Profile. Journal of Autoimmunity, 1994, 7, 55-66.	6.5	42
164	Do Glutamic Acid Decarboxylase Antibodies Improve the Prediction of IDDM in First-degree Relatives At Risk for IDDM?. Journal of Autoimmunity, 1994, 7, 873-879.	6.5	14
165	Defective major histocompatibility complex class I expression on lymphoid cells in autoimmunity. Journal of Endocrinological Investigation, 1994, 17, 547-552.	3.3	0
166	Prevention of xenograft rejection by masking donor HLA class I antigens. Journal of Endocrinological Investigation, 1994, 17, 553-557.	3.3	0
167	Inverse relation between humoral and cellular immunity to glutamic acid decarboxylase in subjects at risk of insulin-dependent diabetes. Journal of Endocrinological Investigation, 1994, 17, 581-584.	3.3	5
168	lodine-induced hyperthyroidism due to nonionic contrast radiography in the elderly. American Journal of Medicine, 1993, 95, 78-82.	1.5	96
169	Inverse relation between humoral and cellular immunity to glutamic acid decarboxylase in subjects at risk of insulin-dependent diabetes. Lancet, The, 1993, 341, 1365-1369.	13.7	262
170	Comparison of Bolus and Infusion Protocols for Determining Acute Insulin Response to Intravenous Glucose in Normal Humans. Diabetes Care, 1993, 16, 911-915.	8.6	34
171	Comparison of Two Commonly Used Standard IVGTTs. Diabetes Care, 1992, 15, 1053-1055.	8.6	10
172	Ovarian Sensitization to Gonadotrophins by Human Growth Hormone. Persistence of the Effect Beyond the Treated Cycle. Obstetrical and Gynecological Survey, 1992, 47, 60-61.	0.4	0
173	Acute continuous hemofiltration with dialysis. Critical Care Medicine, 1992, 20, 1672-1676.	0.9	27
174	Insulin autoantibodies in patients with autoimmune diseases. Diabetes Research and Clinical Practice, 1992, 18, 107-112.	2.8	9
175	Measurement of thyroid-stimulating immunoglobulins by incorporation of tritiated-adenine into intact FRTL-5 cells: a viable alternative to radioimmunoassay for the measurement of cAMP. Clinical Endocrinology, 1992, 37, 493-499.	2.4	8
176	Islet-reactive T cells are a marker of preclinical insulin-dependent diabetes Journal of Clinical Investigation, 1992, 89, 1161-1165.	8.2	61
177	Ovarian sensitization to gonadotrophins by human growth hormone. Persistence of the effect beyond the treated cycle. Clinical Endocrinology, 1991, 35, 119-122.	2.4	30
178	Reactivity to Human Islets and Fetal Pig Proislets by Peripheral Blood Mononuclear Cells From Subjects With Preclinical and Clinical Insulin-Dependent Diabetes. Diabetes, 1991, 40, 1128-1133.	0.6	55
179	Reactivity to human islets and fetal pig proislets by peripheral blood mononuclear cells from subjects with preclinical and clinical insulin-dependent diabetes. Diabetes, 1991, 40, 1128-1133.	0.6	18
180	Double-Blind Controlled Trial of Azathioprine in Children With Newly Diagnosed Type I Diabetes. Diabetes, 1989, 38, 779-783.	0.6	106

#	Article	IF	CITATIONS
181	Ganglioside Expression in Human Pancreatic Islets. Diabetes, 1989, 38, 1478-1483.	0.6	46
182	A prozone phenomenon interferes in islet cell antibody detection: Direct comparison of two methods in subjects at risk of diabetes and in insulin dependent diabetics at onset. Journal of Autoimmunity, 1988, 1, 109-117.	6.5	6
183	Binding of Cytoplasmic Islet Cell Antibodies Is Blocked by Human Pancreatic Glycolipid Extracts. Diabetes, 1988, 37, 645-652.	0.6	99
184	Assay for Islet Cell Antibodies With Rat Pancreas and Peroxidase Protein A. Diabetes Care, 1988, 11, 367-368.	8.6	24
185	Assay for Cytoplasmic Islet Cell Antibodies Using Two-Color Immunofluorescence and Rat Pancreas. Advances in Experimental Medicine and Biology, 1988, 246, 63-69.	1.6	1
186	64,000- <i>M</i> r Autoantigen in Type I Diabetes: Evidence Against Its Surface Location on Human Islets. Diabetes, 1987, 36, 1432-1440.	0.6	32
187	Expression of Cytoplasmic Islet Cell Antigens by Rat Pancreas. Diabetes, 1987, 36, 982-985.	0.6	34
188	EVIDENCE AGAINST AN IMMUNOGENETIC BASIS FOR DIABETES IN CHRONIC PANCREATITIS. Australian and New Zealand Journal of Medicine, 1987, 17, 392-395.	0.5	4
189	Immunotherapy in type I diabetes. Postgraduate Medicine, 1987, 81, 146-155.	2.0	3
190	Interferon-Î ³ Induces the Expression of HLA-A,B,C but Not HLA-DR on Human Pancreatic Î ² -Cells*. Journal of Clinical Endocrinology and Metabolism, 1986, 62, 1101-1109.	3.6	58
191	Expression of Class I MHC Proteins on RIN-m5F Cells Is Increased by Interferon-Â and Lymphokine-Conditioned Medium. Diabetes, 1986, 35, 1225-1228.	0.6	18
192	Nesidioblastosis and Multifocal Pancreatic Islet Cell Hyperplasia in an Adult: Clinicopathologic Features and In Vitro Pancreatic. American Journal of Clinical Pathology, 1985, 84, 534-541.	0.7	22
193	INSULIN SECRETION AND IMMUNOâ€GENETIC MARKERS IN DIABETICS WITH SECONDARY FAILUREâ€~ OF ORAL HYPOGLYCEMIC AGENTS. Australian and New Zealand Journal of Medicine, 1985, 15, 209-212.	0.5	4
194	Increase in Remission Rate in Newly Diagnosed Type I Diabetic Subjects Treated with Azathioprine. Diabetes, 1985, 34, 1306-1308.	0.6	135
195	Adult Human Pancreatic Islet Cells in Tissue Culture: Function and Immunoreactivity*. Journal of Clinical Endocrinology and Metabolism, 1985, 61, 681-685.	3.6	14
196	Structure of insulin/insulin-like growth factor-1 receptors on the insulinoma cell, RIN-m5F. Biochemical and Biophysical Research Communications, 1984, 124, 657-662.	2.1	13